Reimagining Precision Oncology Through AI and Computational Medicine

Abstract

Precision oncology is undergoing a transformative evolution driven by artificial intelligence (AI), computational medicine, and the rapid expansion of multidimensional biomedical data. While conventional precision medicine has largely focused on genomic profiling and targeted therapeutics, emerging computational approaches now integrate radiological imaging, digital pathology, genomics, transcriptomics, proteomics, metabolomics, liquid biopsy, wearable health technologies, electronic health records, and real-world clinical data into comprehensive patient-specific models. Machine learning, deep learning, natural language processing, computer vision, graph neural networks, multimodal learning, transformer architectures, and foundation models have significantly enhanced the ability to interpret these heterogeneous datasets and generate clinically actionable insights. AI-powered computational systems are increasingly supporting early cancer detection, molecular classification, prognostic prediction, biomarker discovery, therapeutic optimization, immunotherapy response assessment, adaptive radiation planning, drug discovery, and intelligent clinical decision support. Emerging innovations including digital twins, spatial biology, federated learning, explainable AI, generative AI, and cloud-enabled healthcare ecosystems further expand the scope of precision oncology by enabling continuously learning models that adapt to evolving patient conditions. Despite remarkable progress, important challenges remain regarding data interoperability, model transparency, cybersecurity, ethical governance, regulatory validation, and equitable implementation. This review explores how artificial intelligence and computational medicine are reimagining precision oncology and shaping the future of individualized cancer care through data-driven clinical intelligence.[1]